Inflammasome Therapeutics is focused on developing therapies for degenerative diseases such as Alzheimer’s disease, multiple sclerosis, macular degeneration, and Parkinson's disease.

Inflammasome Therapeutics

Inflammasome Therapeutics | 341 followers on LinkedIn. Cutting edge treatment for eye diseases and more | Inflammasome Therapeutics is a science based company founded to develop therapies for prevalent, degenerative diseases such as Alzheimer’s disease, multiple sclerosis, macular degeneration, and Parkinson&#39;s disease.

President and CEO at Inflammasome Therapeutics, Ltd.

Paul Ashton

Inflammasome Therapeutics marks the second clinical trial underway with their new drug. Great things are happening at Inflammasome.

Inflammasome Therapeutics announces first patient dosed in Phase 1 Diabetic Macula Edema Study of the Dual Inflammasome Inhibitor K8

Inflammasome Therapeutics has received FDA approval to launch a phase 1/2 first-in-class clinical trial that will evaluate its investigational drug candidate for the treatment of geographic atrophy (GA). Learn more on Glance: https://lnkd.in/gwfYfHbP #GlanceNews Marty Nazzaro LeBlanc Ron

Eyes On Eyecare

Viewport Meta

IPhone / Mobile Compatible

SSL by Default

Euro

Google Font API

Google Analytics

LetsEncrypt

Mobile Non Scaleable Content

Organization Schema

Apache

VP, Research

Jianbing Chen

Senior Vice President Operations

Marty Nazzaro

President and CEO

Principal Consulting Engineer

Steve Perry

Vice President Operations

Jayakrishna Ambati

Co-Founder and Board Member

Co-Founder, CEO, and Board Member

Health Care Companies with Seed Funding (Top 10K)

New England Companies With Less Than $10M in Revenue (Top 10K)

East Coast Health Care Companies (Top 10K)

Greater Boston Area Biotechnology Companies

Inflammasome Therapeutics develops therapies for prevalent, degenerative diseases like Alzheimer’s disease and Parkinson's disease.

Seed Round - Inflammasome Therapeutics

Newton

Massachusetts

United States

North America

Inflammasome Therapeutics Announces First Patient Dosed in Geographic Atrophy (GA) Clinical Trial

Inflammasome Therapeutics Announces First Patient Dosed in Phase I Diabetic Macular Edema Study of the Dual ...

Inflammasome Therapeutics to Enter Clinic with Treatment for Dry AMD

A series of molecules derived from NRTIs that inhibit inflammasome activation without causing mitochondrial toxicity, showing effectiveness in pre-clinical models for diseases like macular degeneration and type 2 diabetes.

Existing FDA-approved drugs for HIV and hepatitis B that have been found to inhibit inflammasome activation and reduce the risk of developing Alzheimer's disease, geographic atrophy, type 2 diabetes, and multiple sclerosis.

India

Asia

news_impact_assignment_basic

key_people

network_dossier

public_peers

news_daily_refresh

news_processing_daily_refresh

news_impact_assignment_daily

news_processing_basic

legal

legal_dossier

bundesanzeiger

events_dossier

partnerships_market_presence_dossier

partnerships_market_presence

company_dossier

network

strategic_challenges

industry_trends

strategic_challenges_dossier

industry_trends_dossier

company_summary

events

network_mapping

transactions_dossier

swot_dossier

merger_acquisitions

signals

financial_statements

crunchbase_trigger

crunchbase_profile

li_profile

financials_download_nd

private_financials

swot_analysis

financial_legal_advisories

company_structure

industry_analysis

financial_analysis

funding_rounds_analysis

regulatory_analysis

competition_analysis

news_impact_assignment_advanced

news_processing_advanced

news_advanced

purchaser_profile

network_onboarding

translate_crunchbase_fundingrounds

peers

customer_profile

news_basic

valuation

news impact assignment basic	general
public peers	general	Nov 19, 2024 5:53 AM	a7b7dc1b
news daily refresh	general
news processing daily refresh	general
news impact assignment daily	general
news processing basic	general
company summary	general
signals	general	Nov 19, 2024 5:53 AM	6845ef19
crunchbase trigger	general	Nov 19, 2024 5:53 AM	cda86bf2
crunchbase profile	general	Nov 19, 2024 11:45 PM	407b0f61
li profile	general	Nov 19, 2024 5:53 AM	cc7d023b
translate crunchbase fundingrounds	general	Nov 20, 2024 12:30 AM	a5a691bb
peers	general	Nov 19, 2024 5:53 AM	f419558d
news basic	general	Nov 19, 2024 5:53 AM	700d6f62
bundesanzeiger	filings
merger acquisitions	company_analysis
financials download nd	financials
private financials	financials

INFL

COM:INFLAM

Inflammasome Therapeutics